NCT04440956View on ClinicalTrials.gov

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

February 25, 2016

Study Completion Date

February 25, 2016

Conditions
Neuroendocrine Tumors
Interventions
DRUG

64Cu-SARTATE

"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY